| Issue Date |
Title |
Author(s) |
| 1-Jun-2022 |
Anti-PD-1 antibody (sintilimab) plus decitabine as first-line treatment for patients with higher-risk myelodysplastic syndrome (MDS): Preliminary results from a single-arm, open-label, phase II study. |
Wang, Jing;Li, Siqi;Jiang, Hao;Chang, Ying-Jun;Zhao, Xiao-Su;Jia, Jin-Song;Zhu, Xiao-Lu;Gong, Li-Zhong;Liu, Xiao-Hong;Yu, Wen-Jing;Huang, Xiao-Jun |
| 2018 |
High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy |
Qin, Ya-Zhen;Zhao, Ting;Zhu, Hong-Hu;Wang, Jing;Jia, Jin-Song;Lai, Yue-Yun;Zhao, Xiao-Su;Shi, Hong-Xia;Liu, Yan-Rong;Jiang, Hao;Huang, Xiao-Jun;Jiang, Qian |
| 2016 |
Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21) |
Zhu, Hong-Hu;Jiang, Hao;Jiang, Qian;Jia, Jin-Song;Qin, Ya-Zhen;Huang, Xiao-Jun |
| 2019 |
Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia |
Xu, Zheng-Li;Zhou, Ming;Jia, Jin-Song;Mo, Wen-Jian;Zhang, Xiao-Hui;Zhang, Yu-Ping;Wang, Yu;Li, Yu-Miao;Huang, Xiao-Jun;Wang, Shun-Qing;Xu, Lan-Ping |
| Jun-2021 |
Interferon-alpha as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia |
Jiang, Hao;Liu, Xiao-Hong;Kong, Jun;Wang, Jing;Jia, Jin-Song;Lu, Sheng-Ye;Gong, Li-Zhong;Zhao, Xiao-Su;Jiang, Qian;Chang, Ying-Jun;Wang, Yu;Ruan, Guo-Rui;Qin, Ya-Zhen;Liu, Kai-Yan;Huang, Xiao-Jun |
| 2017 |
The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia |
Wang, Fang;Jia, Jin-Song;Wang, Jing;Zhao, Ting;Jiang, Qian;Jiang, Hao;Zhu, Hong-Hu |
| 2019 |
Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations |
Deng, Dao-Xing;Zhu, Hong-Hu;Liu, Yan-Rong;Chang, Ying-Jun;Ruan, Guo-Rui;Jia, Jin-Song;Jiang, Hao;Jiang, Qian;Zhao, Xiao-Su;Huang, Xiao-Jun |
| 2019 |
Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate- risk Acute Myelogenous Leukemia in First Complete Remission |
Lv, Meng;Wang, Yu;Chang, Ying-Jun;Zhang, Xiao-Hui;Xu, Lan-Ping;Jiang, Qian;Jiang, Hao;Lu, Jin;Chen, Huan;Han, Wei;Wang, Feng-Rong;Wang, Jing-Zhi;Chen, Yao;Yan, Chen-Hua;Zhang, Yuan-Yuan;Sun, Yu-Qian;Mo, Xiao-Dong;Zhu, Hong-Hu;Jia, Jin-Song;Zhao, Ting;Wang, Jing;Liu, Kai-Yan;Huang, Xiao-Jun |
| Aug-2021 |
PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study |
Tang, Fei-Fei;Lu, Sheng-Ye;Zhao, Xiao-Su;Qin, Ya-Zhen;Liu, Xiao-Hong;Jia, Jin-Song;Wang, Jing;Gong, Li-Zhong;Jiang, Qian;Zhao, Ting;Shi, Hong-Xia;Chang, Ying-Jun;Huang, Xiao-Jun;Jiang, Hao |
